Lecanemab deliberations at the CHMP regarding the Marketing Authorisation Application in the EU have been rescheduled due to procedural reasons ...Middle East

STOCKHOLM, March 22, 2024 /PRNewswire/ -- BioArctic AB:s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Oral Explanation scheduled for March 19 at the Committee for Medicinal Products for Human Use (CHMP) for lecanemab, which is currently under review by the...

Hence then, the article about lecanemab deliberations at the chmp regarding the marketing authorisation application in the eu have been rescheduled due to procedural reasons was published today ( Friday 22/03/2024 - 02:53 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Lecanemab deliberations at the CHMP regarding the Marketing Authorisation Application in the EU have been rescheduled due to procedural reasons )

Also on site :

• This New Iron Maiden x Timex Watch Features a Light-Up Cyborg Eddie. Here’s Where to Preorder It Early
• Crews tackle vegetation fire on Farren Road in Goleta
• Alaska Airlines Debuts 1st-Ever Transatlantic 737 MAX Flight to the Land of Geothermal Lagoons and Northern Lights